Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.
The Journal of dermatological treatment · Dec 1, 2026
What's New: Upadacitinib 30 mg ranked highest in efficacy across all evaluated outcomes among approved systemic therapies for moderate-to-severe atopic dermatitis.
Read more →